Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12812
Peer-review started: August 23, 2022
First decision: October 24, 2022
Revised: November 4, 2022
Accepted: November 28, 2022
Article in press: November 28, 2022
Published online: December 16, 2022
Processing time: 112 Days and 20.2 Hours
Minimally invasive adrenalectomy has become the main treatment modality for most adrenal lesions. Both laparoscopic transabdominal and retroperitoneoscopic approaches are safe and feasible options, each with respective advantages, including better surgical outcomes, fewer complications, and faster recovery over open adrenalectomy. While open surgery remains a valid modality in treatment of adrenocortical cancer in the presence of some findings such as invasion, robotic platforms, and minimally invasive surgery have gained popularity as technology continues to evolve. Organ preservation during adrenalectomy is feasible in some conditions to prevent adrenal insufficiency. Ablative technologies are increasingly utilized in benign and malignant tumors, including the adrenal gland, with various outcomes. A multidisciplinary team, an experienced surgeon, and a high-volume center are recommended for any surgical approaches and management of adrenal lesions. This review article evaluated recent findings and current evidence on minimally invasive adrenalectomy.
Core Tip: Minimally invasive adrenalectomy is the standard treatment for most adrenal lesions. Options to approach the adrenal gland include a transabdominal or retroperitoneoscopic route via laparoscopy or robotic platform. While each presents their own advantages, all are safe and produce excellent outcomes. Although open surgery for adrenocortical carcinoma remains suitable in some situations, partial adrenalectomy may be appropriate in certain cases to prevent adrenal insufficiency.